Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia

Med J Aust. 2021 Sep 20;215(6):245-249.e1. doi: 10.5694/mja2.51229. Epub 2021 Sep 6.

Authors

Vivien M Chen^{1

2}, Jennifer L Curnow³, Huyen A Tran^{4

5}, Philip Y-I Choi⁶

Affiliations

¹ Concord Hospital, Sydney, NSW.
² ANZAC Research Institute, University of Sydney, Sydney, NSW.
³ Westmead Hospital, Sydney, NSW.
⁴ Alfred Hospital, Melbourne, VIC.
⁵ Central Clinical School, Monash University, Melbourne, VIC.
⁶ Canberra Hospital, Canberra, ACT.

No abstract available

Keywords: Thrombosis; Vaccination.

Publication types

Case Reports

MeSH terms

Ad26COVS1
Adult
Aged, 80 and over
Algorithms
Anticoagulants / administration & dosage
Anticoagulants / therapeutic use
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / diagnosis
Australia / epidemiology
COVID-19 / diagnosis
COVID-19 / epidemiology
COVID-19 / prevention & control*
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / adverse effects*
ChAdOx1 nCoV-19
Combined Modality Therapy / methods
Enzyme-Linked Immunosorbent Assay / methods
Female
Humans
Immunoglobulins, Intravenous / administration & dosage
Immunoglobulins, Intravenous / therapeutic use
Male
Mass Screening / methods
Middle Aged
New Zealand / epidemiology
Platelet Factor 4 / drug effects
Platelet Factor 4 / immunology
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
Purpura, Thrombocytopenic, Idiopathic / diagnosis
Purpura, Thrombocytopenic, Idiopathic / drug therapy
SARS-CoV-2 / genetics
SARS-CoV-2 / immunology
Thrombosis / chemically induced*
Thrombosis / diagnosis
Thrombosis / drug therapy

Substances

Ad26COVS1
Anticoagulants
COVID-19 Vaccines
Immunoglobulins, Intravenous
Platelet Factor 4
ChAdOx1 nCoV-19